z-logo
Premium
Adeno‐associated virus serotype 9 administered systemically after reperfusion preferentially targets cardiomyocytes in the infarct border zone with pharmacodynamics suitable for the attenuation of left ventricular remodeling
Author(s) -
Konkalmatt Prasad R.,
Wang Feng,
Piras Bryan A.,
Xu Yaqin,
O'Connor Daniel M.,
Beyers Ronald J.,
Epstein Frederick H.,
Annex Brian H.,
Hossack John A.,
French Brent A.
Publication year - 2012
Publication title -
the journal of gene medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.689
H-Index - 91
eISSN - 1521-2254
pISSN - 1099-498X
DOI - 10.1002/jgm.2673
Subject(s) - luciferase , genetic enhancement , gene delivery , medicine , troponin complex , gene expression , systemic administration , microbiology and biotechnology , cardiology , myocardial infarction , biology , in vivo , gene , transfection , troponin i , biochemistry
Background Adeno‐associated virus serotype 9 (AAV9) vectors provide efficient and uniform gene expression to normal myocardium following systemic administration, with kinetics that approach steady‐state within 2–3 weeks. However, as a result of the delayed onset of gene expression, AAV vectors have not previously been administered intravenously after reperfusion for post‐infarct gene therapy applications. The present study evaluated the therapeutic potential of post‐myocardial infarction gene delivery using intravenous AAV9. Methods AAV9 vectors expressing firefly luciferase, enhanced green fluorescent protein (eGFP) or extracellular superoxide dismutase genes from the cardiac troponin‐T (cTnT) promoter (AcTnTLuc, AcTnTeGFP, AcTnTEcSOD) were employed. AcTnTLuc was administered intravenously at 10 min and at 1, 2 and 3 days post‐ischemia/reperfusion (IR), and the kinetics of luciferase expression were assessed with bioluminescence imaging. AcTnTeGFP was used to evaluate the distribution of eGFP expression. High‐resolution echocardiography was used to evaluate the effects of AcTnTEcSOD on left ventricular (LV) remodeling when injected 10 min post‐IR. Results Compared to sham animals, luciferase expression at 2 days after vector administration was elevated by four‐, 24‐, 210‐ and 213‐fold in groups injected at 10 min, 1 day, 2 days and 3 days post‐IR, respectively. The expression of cTnT‐driven eGFP was strongest in cardiomyocytes bordering the infarct zone. In the efficacy study of EcSOD, post‐infarct LV end‐systolic and end‐diastolic volumes at days 14 and 28 were significantly smaller in the EcSOD group compared to the control. Conclusions Systemic administration of AAV9 vectors after IR both elevates and accelerates gene expression that preferentially targets cardiomyocytes in the border zone with pharmacodynamics suitable for the attenuation of LV remodeling. Copyright © 2012 John Wiley & Sons, Ltd.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here